Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635074 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Steven E. Coutre.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02635074 is a Phase 1 study that was terminated before completion, run by Steven E. Coutre. The registered enrollment target is 2 participants.
The verdict
NCT02635074, a Phase 1 study, was terminated before completion, sponsored by Steven E. Coutre.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ibrutinib when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has returned after a period of improvement or has not responded to previous treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib together with idarubicin and cytarabine may kill more cancer cells.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635074
The ClinicalTrials.gov registry entry for NCT02635074 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven E. Coutre, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02635074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635074 about?
NCT02635074 is a clinical study titled "Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of ibrutinib when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has returned after a period of improvement or has not responded to previous treatment. Ibrutinib may stop the growth of canc...
What is the current status of trial NCT02635074?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-11. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02635074?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02635074?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.